NDA 021642 · Endo Operations
Nascobal
Cyanocobalamin · Nasal · Vitamin B12
DiscontinuedLast checked: Nov 20, 2026Latest source record: Dec 7, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Jan 31, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
305
74 Phase 3, 22 recruiting
FAERS reports
33,402
24,688 serious, 3,369 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 1, 2024.
NASCOBAL is indicated for: Vitamin B 12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement Treatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B 12 deficiency not due to pernicious anemia Prevention of vitamin B 12 deficiency in adult patients with vitamin B 12 requirements in excess of normal Limitations of Use NASCOBAL should not be used for the vitamin B 12 absorption test (Schilling test). In patients with correctible or temporary causes of vitamin B 12 deficiency, the benefit of continued long-term use of NASCOBAL following adequate correction of vitamin B 12 deficiency and underlying disease has not been established. The effectiveness of NASCOBAL in patients with active symptoms of nasal congestion, allergic rhinitis or upper respiratory infection has not been determined. Treatment with NASCOBAL should be deferred until symptoms have subsided. NASCOBAL is a vitamin B 12 indicated for: Vitamin B12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement (1) Treatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B12 deficiency not due to pernicious anemia (1) Prevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements in excess of normal (1) Limitations of Use: Should not be used for the vitamin B12 absorption test (Schilling test). (1) In patients with correctible or temporary causes of vitamin B12 deficiency the benefit of continued long-term use following correction of vitamin B 12 deficiency and underlying disease has not been established....
Mechanism: Vitamin B 12 can be converted to coenzyme B 12 in tissues, and as such is essential for conversion of methylmalonate to succinate and synthesis of methionine from homocysteine, a reaction which also requires folate. In the absence of coenzyme B 12 , tetrahydrofolate cannot be regenerated from its inactive storage form, 5-methyltetrahydrofolate, and a functional folate deficiency occurs. Vitamin B 12 also may be involved in maintaining sulfhydryl (SH) groups in the reduced form required by many SH-activated enzyme systems. Through these reactions, vitamin B 12 is associated with fat and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- NASCOBAL · CYANOCOBALAMIN 0.5MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SPRAY, METERED, NASAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Cyanocobalamin" as an intervention, any sponsor and status, largest first.
- Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)Pivotal-lookingStatus unknown
Kafrelsheikh UniversityAcademic, hospital or other
NCT04353180 · 100,000 participants (planned) · Start Aug 2021 · Primary completion Oct 2021
Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment; Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment and 3 more · For: COVID19
Sites: Cairo, Egypt · 2 sites in all
- Study of the Effectiveness of Additional Reductions in Cholesterol and HomocysteinePivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00124072 · 12,064 participants · Start Jul 1998 · Primary completion May 2008
Drug: Simvastatin 20 mg daily; Simvastatin 80 mg daily and 1 more · For: Cardiovascular Disease
Sites: Oxford, United Kingdom
- VITATOPS: A Study of VITAmins TO Prevent StrokePivotal-lookingCompleted
VITATOPSGovernment (non-federal)
NCT00097669 · 8,164 participants · Start Nov 1998 · Primary completion Jun 2009
Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo · For: Stroke; Transient Ischemic Attack
Sites: New York, New York; Abington, Pennsylvania; Columbia, South Carolina · 111 sites in all
- HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)Pivotal-lookingStatus unknown
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT00106886 · 5,000 participants · Start Dec 1999
Drug: Folic acid, vitamin B6 and B12 or placebo · For: Cardiovascular Disease; Myocardial Infarction; Stroke and 1 more
Sites: Hamilton, Canada
- Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)Pivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00064753 · 4,110 participants · Start May 2002 · Primary completion Oct 2011
Drug: High Dose Multivitamin · For: Chronic Kidney Disease; Cardiovascular Disease; Death
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 30 sites in all
- The Norwegian Vitamin Trial (NORVIT)Pivotal-lookingCompleted
University of TromsoAcademic, hospital or other
NCT00266487 · 3,750 participants · Start Dec 1998
Drug: Folic acid; Vitamin B12 and 1 more · For: Acute Myocardial Infarction
Sites: Tromsø, Norway
- WENBIT - Western Norway B Vitamin Intervention TrialPivotal-lookingCompleted
Haukeland University HospitalAcademic, hospital or other
NCT00354081 · 3,096 participants · Start Apr 1999 · Primary completion Jun 2007
Drug: folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine); folic acid, vitamin B12 (cyanocobalamin) and 2 more · For: Coronary Artery Disease; Myocardial Infarction; Cerebrovascular Stroke
Sites: Bergen, Norway; Stavanger, Norway
- A Trial of Zinc and Micronutrients in Tanzanian ChildrenPivotal-lookingCompleted
Harvard School of Public Health (HSPH)Academic, hospital or other
NCT00421668 · 2,400 participants · Start Sep 2007 · Primary completion Oct 2012
Drug: Zinc; Multivitamins and 1 more · For: Diarrheal Illnesses; Respiratory Illness; Growth Faltering
Sites: Dar es Salaam, Tanzania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue3,394
- nausea2,796
- off label use2,518
- headache2,426
- pain2,258
- diarrhoea2,242
- drug ineffective2,238
- dyspnoea2,152
- vomiting1,845
- arthralgia1,817
- asthenia1,793
- fall1,747
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 230 |
| 2005 | 298 |
| 2006 | 474 |
| 2007 | 254 |
| 2008 | 443 |
| 2009 | 341 |
| 2010 | 388 |
| 2011 | 391 |
| 2012 | 628 |
| 2013 | 584 |
| 2014 | 759 |
| 2015 | 1,111 |
| 2016 | 1,665 |
| 2017 | 1,732 |
| 2018 | 2,066 |
| 2019 | 2,362 |
| 2020 | 2,449 |
| 2021 | 2,471 |
| 2022 | 3,223 |
| 2023 | 2,916 |
| 2024 | 3,256 |
| 2025 | 3,250 |
| 2026 | 2,111 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- B Vitamins as Adjunctive Treatment for Chronic Heart Failure.
Dkhillon D, Samogulova A, Kolobov B · Cardiovasc Hematol Disord Drug Targets 2023 · Network Meta-Analysis
- B vitamins in stroke prevention: time to reconsider.
Spence JD, Yi Q, Hankey GJ · Lancet Neurol 2017 · Meta-Analysis, Review
- [Update of oral vitamin B12].
Andres E, Serraj K, Mecili M, et al. · Ann Endocrinol (Paris) 2009 · Systematic Review
- Folic acid with or without vitamin B12 for cognition and dementia.
Malouf M, Grimley EJ, Areosa SA · Cochrane Database Syst Rev 2003 · Systematic Review
- Systematic review and meta-analysis of randomized placebo-controlled trials of folate and vitamin B12 for depression.
Almeida OP, Ford AH, Flicker L · Int Psychogeriatr 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- The Oral Bioavailability of Vitamin B12 at Different Doses in Healthy Indian Adults.
Kashyap S, Gowda P, Pasanna RM, et al. · Nutrients 2024 · Randomized Controlled Trial
Sponsor: Endo Operations
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.